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genotype distribution among hybrid capture 2
positive women 15 to 64 years of age in the
Gurage zone, rural Ethiopia
Sami-Ramzi Leyh-Bannurah1, Christof Prugger2,3, Maurits NC de Koning4, Hartmut Goette5 and Ralph J Lellé1*Abstract
Background: Human papillomavirus (HPV) infection is a prerequisite of cervical cancer, the leading cause of cancer
mortality in Ethiopian women today. Data on Ethiopian cervical HPV prevalence and genotype distribution are rare,
but essential as pre-vaccine baseline data to monitor changes after initiating HPV vaccination. The objectives of this
study were to assess the cervical HPV prevalence, genotype distribution and associated correlates among female
hospital outpatients in rural Ethiopia.
Methods: We examined a consecutive sample of 537 women 15–64 years of age in rural Ethiopia between
November and December 2006. Screening for low risk (LR) and high-risk (HR) cervical HPV infection was performed
and HR positive samples were genotyped with a GP5+/6 + − and SPF10-primer based system.
Results: The age-standardized prevalence of HPV, HPV HR and HPV LR infection was 17.3% (95% CI 14.1-20.5), 15.8%
(95% CI 12.7-18.9) and 3.9% (95% CI 2.3-5.6), respectively. Among HC2 HPV HR positive infections (n = 86), the most
common genotype was HPV 16 (24.4%), followed by 52 (11.6%), 56 (10.5%) and 31 (10.5%). Non-married relationship
and widowhood, increasing number of lifetime sexual partners, human immunodeficiency virus infection and
non-traditional housing type, but not age, were significantly associated with HR HPV infection.
Conclusions: These results on cervical HPV prevalence and genotype distribution may serve as baseline data in
evaluating the impact of future HPV vaccination programmes in rural Ethiopia.
Keywords: Papillomavirus infections, Cervix uteri, Ethiopia, DNA probes, HPV, Epidemiology, Risk factors, Sub-Sahara AfricaBackground
In the year 2012, estimates of the worldwide number of
cervical cancer cases and deaths amounted to 527,624
and 265,653, respectively [1]. More than 80% of global
invasive cervical cancer (ICC) cases occur in developing
countries and come with a higher mortality/incidence
ratio [2]. National cervical cancer screening only covers
less than 1% of the female population in Ethiopia, where
ICC is associated with the highest cancer mortality
among women [2]. For 2012, the estimated age-
standardized incidence and mortality rates were 26.4* Correspondence: office@lellenet.de
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article, unless otherwise stated.and 18.4 per 100,000 Ethiopian women, respectively,
corresponding to a 4- and 9-times higher incidence and
mortality rate than in Western Europe [1].
Persistent high-risk (HR) HPV infection is a prerequisite
for the development of cervical cancer [3]. Because nation-
wide cervical cancer screening is rarely established in
countries with limited resources, HPV vaccination pro-
grammes may be an alternative and cost-effective option
in these settings [4]. However, there is great hete-
rogeneity with regard to the country-specific HPV
prevalence, type-specific distribution and associated
characteristics across age groups that must be consi-
dered prior to introducing HPV vaccination [5,6]. More-
over, such baseline data are very limited in Ethiopia, butCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in HPV type-specific distributions by HPV target eva-
sion that could possibly limit the effect of HPV vac-
cination [7,8].
In the present study, we report on the prevalence of
cervical HPV infection, the distribution of HPV geno-
types and determinants of HPV HR infection among
hospital outpatients from rural Ethiopia.
Methods
Study population
Attat Hospital is located in the rural Gurage zone, central
Ethiopia. The estimated catchment area of the hospital
comprises around 1 million inhabitants [9]. Between
November and December 2006, a consecutive sample of
537 women 15 to 64 years of age who visited the out-
patient department were recruited with the aim of inclu-
ding 50 women from each 5-year age group. Main causes
of outpatient visits were gynaecological diseases, perinatal
care, and respiratory tract and gastrointestinal infections.Hybrid Captur
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Figure 1 Flow diagram of sample processing. HPV screening by Hybrid
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system, version 1, of all HC2 HR HPV positive samples, in which no HPV type w
number (%) of results in relation to the preceding assay performed.Women were included if they reported to have been
sexually active. Exclusion criteria were a history of hys-
terectomy, presence of conisation and physical or mental
inability to attend the interview and pelvic examination. A
total of 4 patients refused participation. At enrolment, all
women provided written informed consent.
Data collection
One senior gynaecologist performed all gynaecological ex-
aminations, and the cervix could be visualized in all
women using a Cusco speculum. Cervical samples were
collected using a swab (digene Cervical Sampler, Qiagen,
Hilden, Germany) and stored at −10°C for later HPV de-
tection and genotyping. The questionnaire was translated
into Amharic and back to English to ensure equivalence.
It covered sociodemographic, sexual and reproductive
characteristics, and lifestyle habits. Among 235 patients
(43.8%) who were not able to report their age or date of
birth, age was estimated by the senior gynaecologist in
consensus with the medical nurse.SPF10-DEIA
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Figure 2 Age-specific prevalence (%) of cervical human
papillomavirus infection. Low risk, high risk and overall HPV
prevalence and corresponding 95% confidence intervals according to
ten-year age groups among 537 women, Gurage zone, rural Ethiopia.
Results are based on DNA detection by Hybrid Capture 2 DNA test.
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The digene Hybrid Capture 2 HPV DNA Test ([HC2]
Qiagen, Hilden, Germany) was performed according to
manufacturer’s specifications at the Cytopathology Labora-
tory of the Department of Gynaecology and Obstetrics,
University of Muenster, Germany, as described previously
[10]. Using the HR HPV probe, 13 HR HPV types (16/ 18/
31/ 33/ 35/ 39/ 45/ 51/ 52/ 56/ 58/ 59/ 68) can be col-
lectively detected without identifying the HPV genotype.
Similarly, five low-risk (LR) HPV types (6/ 11/ 42/ 43/ 44)
can be detected with the LR HPV probe.
All HC2 HR HPV positive samples were further analysed
at DDL Diagnostic Laboratory (Rijswijk, Netherlands). An
overview of the HPV detection and consecutive HPV
genotyping algorithm is shown in Figure 1.
HPV genotyping
The quality of the isolated DNA was checked by ampli-
fying a 268 base pair fragment from the ß-globin gene
with primers PC04 and GH20 [11]. First, the Genotyping
Kit HPV GP (Diassay BV, Rijswijk, The Netherlands)
was used according to the instructions of the manufac-
turer [12]. This kit identifies 14 HR genotypes (16/ 18/
31/ 33/ 35/ 39/ 45/ 51/ 52/ 56/ 58/ 59/ 66/ 68 with sub-
type 68a) and 4 possible HR HPV types (26/ 53/ 73/ 82
with subtypes IS39 and MM4). Second, in HC2 HR HPV
positive samples in which no HPV type was identified
by the Genotyping Kit HPV GP (n = 27; Figure 1), the
highly sensitive SPF10-LiPA25, version 1 system (Labo
Bio-medical Products, Rijswijk, The Netherlands) was
used for further evaluation of HPV genotypes as described
previously [13]. The SPF10-DNA Enzyme Immuno Assay
(DEIA) allows a pooled broad spectrum HPV detection of
more than 54 HPV types and the SPF10-line probe assay
(LiPA) enables subsequent genotyping of 25 different LR
and HR HPV genotypes (6/ 11/ 16/ 18/ 31/ 33/ 34/ 35/
39/ 40/ 42/ 43/ 44/ 45/ 51/ 52/ 53/ 54/ 56/ 58/ 59/ 66/
“68/73”/ 70/ 74). Genotypes 68 and 73 cannot be discrimi-
nated by the LiPA [13].
Statistical analysis
Descriptive statistics are presented as numbers (%) and
median (interquartile range, IQR). Prevalence estimates
were age standardised using the world standard popula-
tion as reported by Doll et al. [14]. Associations of patient
characteristics with HPV HR infection were assessed using
logistic regression analysis to estimate odds ratios (ORs)
with 95% confidence intervals (CI). A multivariable model
was fitted using backward selection among variables
identified in univariate analyses using an entry threshold
of p < 0.10. All tests were two-sided and an alpha level of
0.05 was chosen to indicate statistical significance. Ana-
lyses were performed using SPSS 18.0.3 (IBM, New York,
USA).Results
Patient characteristics
Median age at onset of menstrual bleeding was 13 years
(IQR 13–14), age at sexual debut and first pregnancy
were both at 18 years (IQRs 15–20 and 15–21, respec-
tively). The median number of life births reported was 4
(IQR 2–7).
Overall, 391 (72.8%) women were in a monogynous
marriage and 102 (19.0%) were widowed. Median length
of partnership was 9 years (IQR 3–19). The median
number of lifetime sexual partners was 1 (IQR 1–1),
with 123 (22.9%) women having more than one lifetime
sexual partner. 404 (75.2%) patients denied to have ever
used any contraceptive method.
Frequency of HPV infections
Figure 1 shows the flow chart of sample processing. The
frequency of HPV HR and LR infection was 16.0% and
3.9%, respectively. A HPV HR and LR co-infection was
present in 13 (2.4%) women. Thus, a total of 94 (17.5%)
women were classified as HPV positive by HC2. The
age-standardized prevalence of HPV, HR HPV and LR
HPV infection amounted to 17.3% (95% CI 14.1-20.5),
15.8% (95% CI 12.7-18.9) and 3.9% (95% CI 2.3-5.6),
respectively.
Figure 2 shows the frequency of HPV, HR HPV and LR
HPV infections by 10-year age groups. Neither the
frequency of HPV, nor the one of HR HPV and LR HPV
infections showed a significant age pattern (p for trend =
0.473, 0.566 and 0.571, respectively).
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All 86 HC2 HR HPV positive samples were used for
subsequent HPV genotyping. As shown in Figure 1, pri-
mary testing by the Genotyping Kit HPV GP identified
the HPV type in 59 samples (68.6%). Further testing
with the highly sensitive SPF10-LiPA25, version 1, ad-
ditionally identified 15 HR HPV (partially with HPV co-
infections) and two LR mono-infections. Despite being
SPF10 DEIA positive, one sample remained LiPA nega-
tive, indicating the presence of another type than the 25
HPV types included on the LiPA. An exact genotype
could not be identified.
Table 1 presents the cervical HPV genotype distribution
identified by Genotyping Kit HPV GP and SPF10-LiPA25
system, version 1, among HC2 HR HPV positive infec-
tions (n = 86). Table 2 allows discriminating between the
genotyping results of both PCR assays. Among HC2 HR
HPV positive infections (n = 86), the most common geno-
type was HPV 16 (24.4%), followed by 52 (11.6%), 56
(10.5%), 31 (10.5%), 51 (7.0%), 35 and 39 (both 5.8%), 45Table 1 Cervical HPV genotype distribution and phylogenetic
Gurage zone, rural Ethiopia
HPV genotypes*
Number of HPV infection
Single Multiple**
11a 1 0
16 16 5
18 1 2
31 6 3
33 1 1
35 4 1
39 4 1
43a 0 1
45 3 1
51 5 1
52 7 3
53 1 0
56 5 4
58 2 0
59 1 0
66 2 0
68 2 2
70a 1 1
73 0 1
82 1 0
68/73b 2 0
*Genotypes identified in HC2 high risk positive infections by Genotyping Kit HPV G
**Only HPV high risk co-infections were considered.
aHPV low-risk genotype.
bDiscrimination between HPV genotypes 68 and 73 is not possible with SPF10-LiPAand 68 (both 4.7%), and 18 (3.5%). Overall, 17 different
HR and 3 different LR HPV genotypes were identified,
amounting to a total of 92 HR or LR infections. In this
group, 49 (53.3%), 19 (20.7%) and 12 (13.0%) HPV infec-
tions were attributed to species α9 (HPV 16, 31, 33, 35,
52, 58, 67), α7 (HPV 18, 39, 45, 59, 68, 70) and α6 (HPV
53, 56, 66), respectively, based on their phylogenetic classi-
fication [15]. Furthermore, in this group, 24 (26.1%) and
52 (56.5%) HPV infections would be targeted by a current
bivalent (types 16 and 18) and an impending next genera-
tion nonavalent (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)
HPV vaccine, respectively [16].
Univariate and multivariable associations with HPV HR
infection
In univariate analyses for the association with HPV HR in-
fection, the following patient characteristics did not reach
the threshold of p < 0.10: religion, educational level of the
women and their partner, patient’s income, age at mena-
rche, parity, current pregnancy, female circumcision,classification among HC2 high risk positive women,
s n = 86 Phylogeneticclassification
Total Percent Species
1 1.2 α10
21 24.4 α9
3 3.5 α7
9 10.5 α9
2 2.3 α9
5 5.8 α9
5 5.8 α7
1 1.2 α8
4 4.7 α7
6 7.0 α5
10 11.6 α9
1 1.2 α6
9 10.5 α6
2 2.3 α9
1 1.2 α7
2 2.3 α6
4 4.7 α7
2 2.3 α7
1 1.2 α11
1 1.2 α5
2 2.3 α7 or α11
P and SPF10-LiPA25, version 1.
25 system, version 1.
Table 2 Cervical HPV infection stratified by results of
Genotyping Kit HPV GP and SPF10-LiPA25, version 1
among HC2 high risk positive women, Gurage zone, rural
Ethiopia
HPV infection Total
HPV genotype
by genotyping
Kit HPV GP
HPV genotype
by SPF10-LiPA25,
ver. 1*
n n n
11a 1 1
16 16 16
18 1 1
31 6 6
33 1 1
35 4 4
39 4 2 2
45 2 2
51 5 1 4
52 7 4 3
53 1 1
56 5 5
58 2 1 1
59 1 1
66 2 2
68 2 2
70a 1 1
82 1 1
68/73b 2 2
16,56 2 2
18,52 1 1
18,56 1 1
31,56 1 1
31,68 1 1
39,73 1 1
45,70a 1 1
16,31,35 1 1
16,33,68 1 1
16,45,52 1 1
43a,51,52 1 1
*Only samples negative by Genotyping Kit HPV GP were tested by SPF10-LiPA25,
version 1.
aHPV low-risk genotype.
bDiscrimination between HPV genotypes 68 and 73 is not possible with
SPF10-LiPA25, version 1.
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Table 3 presents univariate and multivariable associations
with HPV HR infection of the remaining patient charac-
teristics under investigation: non-married relationship and
widowhood, increasing number of lifetime sexual partners,
human immunodeficiency virus infection (HIV) and non-traditional housing type were independently associated
with HR HPV infection.
Discussion
The present study reports on the prevalence of cervical
HPV infection, the distribution of HPV genotypes and
determinants of HPV HR infection in rural Ethiopia.
Our study reveals several important findings.
HPV prevalence
We observed an age-standardised prevalence of HPV in-
fection of 17.3% and an age-standardised prevalence of
HPV HR infection of 15.8%. A review by Smith et al.
reported great variations in the HPV prevalence across
African countries ranging from 12% to 46% [17]. Spe-
cifically, studies from the Sub-Saharan African countries
Nigeria [18], Uganda [19] and Mozambique [20] re-
ported HPV HR frequencies of 14.7%, 19.2% and 40.0%,
respectively. In comparison, HR HPV prevalence esti-
mates for developed countries in Western Europe range
from 9.4% to 12.1% [21]. Thus, our study results indicate
that the HPV HR prevalence in rural Ethiopia is consis-
tent with reports from Sub-Saharan Africa, but almost
twice as high as in most Western European countries.
No significant age pattern was observed, despite inclu-
ding the rarely reported age interval of 15 years up to
64 years in our study. However, instead, there was a rather
high HPV HR prevalence of at least 10% in each 10-year
age group. Worldwide and African studies reported hete-
rogeneous age patterns: HPV HR prevalence decreasing
with age [5,19,22], showing an U-shaped curve [22,23] or
being consistently high across all age groups [5,20,24].
The latter is the case in the present study, possibly indica-
ting a lifespan HPV persistence and/or a reacquisition
with increasing age due to changing sexual behaviour and
age-related changes of mucosal biology and immune com-
petence [5,23]. This is also consistent with our result on
widowhood, which increased with age, as a correlate for
HR HPV infection.
HPV genotypes
The 5 most common HPV genotypes in our study sample
were HPV 16 (24.4%), followed by 52 (11.6%), 56 (10.5%)
and 31 (10.5%) and 51 (7.0%). Among women with normal
cytology, HPV types 16, 18, 31, 58, 52 and 52, 16, 18, 53,
66 are estimated to be the most common worldwide and
in Eastern Africa, respectively [22]. Our study reveals
HPV genotypes 16 and 52 as predominant genotypes in
Ethiopia. HPV 16 has the highest carcinogenic potential
and is targeted by current HPV vaccines [15]. Nonetheless,
as expected, also oncogenic HR HPV genotypes were
identified, which are not targeted by current and adver-
tised polyvalent vaccines [16]. However, HPV vaccination
remains a promising approach in Ethiopia for multiple
Table 3 Odds ratios for HR HPV positivity and corresponding 95% CIs by selected characteristics, Gurage zone, rural
Ethiopia
HC2 HR positivity Univariable Multivariable
n/total % OR 95% CI p-value AOR 95% CI p-value
Age interval
15-24 16/111 14 1.00 0.572
25-34 17/104 16 1.16 (0.55 - 2.44) 0.695
35-44 21/106 20 1.47 (0.72 - 2.99) 0.292
45-54 13/109 12 0.80 (0.37 - 1.76) 0.586
55-64 19/107 18 1.28 (0.62 - 2.65) 0.502
Marital status
Married, monogynous 51/391 13 1.00 0.021 1.00 0.047
Married, polygynous 4/18 22 1.91 (0.60 - 6.01) 0.272 1.26 (0.35 - 4.57) 0.728
With Partner (not married) 3/6 50 6.67 (1.31 - 33.93) 0.022 7.22 (1.37 - 38.10) 0.020
Divorced or separated 4/20 20 1.67 (0.54 - 5.18) 0.378 0.66 (0.16 - 2.69) 0.561
Widowed 24/102 24 2.05 (1.19 - 3.53) 0.010 1.85 (1.01 - 3.41) 0.047
Lifetime number of sexual partners
1 55/414 13 1.00 0.004 1.00 0.011
2 25/106 24 2.01 (1.18 - 3.43) 0.010 1.83 (1.03 - 3.23) 0.039
≥ 3 6/17 35 3.56 (1.27 - 10.02) 0.016 3.94 (1.33 - 11.65) 0.013
History of STD
Never 71/502 14 1.00 < 0.001 1.00 0.002
Other STD than HIV* 4/14 29 2.43 (0.74 - 7.95) 0.143 1.95 (0.57 - 6.69) 0.291
HIV 9/12 75 18.21 (4.81 - 68.90) < 0.001 13.59 (3.25 - 56.89) < 0.001
Unknown/unsure 2/9 22 1.73 (0.35 - 8.52) 0.498 2.47 (0.49 - 12.45) 0.274
Main house
Traditional thatched house (gojo) 60/429 14 1.00 1.00
Other 26/108 24 1.95 (1.16 - 3.28) 0.012 1.98 (1.10 - 3.57) 0.022
Results are based on high risk HPV DNA detection by Hybrid Capture 2 DNA test and presented among 537 women.
*Other STDs reported were gonorrhea, syphilis and chlamydia infection; 95% CI = 95% confidence interval; AOR = adjusted odds ratio; HC2 = hybrid capture 2 HPV
test; HIV = human immunodeficiency virus; OR = odds ratio; STD = sexually transmitted disease.
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against non-vaccine type HPVs [25,26]. Second, many
oncogenic HPV infections that evade the vaccine target
range are transient and do not reach relevant stages of cer-
vical carcinogenesis [27]. Third, specifically in settings like
Ethiopia with very limited resources and poor cervical can-
cer screening coverage, HPV vaccination may represent a
definitive prevention strategy. Our data on Ethiopian HPV
prevalence and genotype distribution would represent a
first step to build baseline data enabling to monitor dy-
namics in HPV genotype distribution as an effect of HPV
vaccination that can be registered earlier than changes in
(pre)cancerous cervical lesions, which naturally can take
decades. However, Ethiopian data collection on baseline
HPV type prevalence in ICC patients also remains a prior-
ity so that long term HPV vaccine efficacy can be finally
evaluated.In our study, HPV types 18, 53 and 66 were not corrob-
orated as other common types in Eastern Africa, but were
rather rare [22]. First, this might be attributed to the low
share of African studies in worldwide reviews, i.e. only
3.9% in a meta-analysis by de Sanjose et al. [22] and thus
limited data from African regions. Second, HPV results
from various populations often differ by age ranges, set-
tings and HPV assays used [28], which makes comparisons
difficult. However, our study includes a wide age range
(15–64 years), a balanced age distribution of at least 50
participants per 5-year age group and established HC2
HPV screening with a sophisticated two-step genotyping
algorithm.
Correlates of HC2 HR HPV infection
Our analyses revealed that non-married relationship and
widowhood, increasing number of lifetime sexual partners,
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non-traditional housing type were independently asso-
ciated with HR HPV infection. These results are in line
with previous reports showing that marital status, num-
ber of lifetime sexual partners and history of STDs, par-
ticularly HIV, are established risk factors for HR HPV
infection [3,19,28,29].
A housing type other than gojo, presumably depicting
a higher socioeconomic status or an urban living area,
was positively associated with HPV HR infection. Con-
versely to this finding, many studies have described an
increased risk of HPV infection with lower socio-
economic status [30]. Possibly, living in rural areas can
be beneficial with regard to female health status in our
study setting. Supporting this theory is a 11-fold dif-
ference in HIV prevalence between rural and urban
areas in Ethiopia (0.7% versus 7.7%, respectively) [31].
Neither parity nor age at first pregnancy nor use of oral
contraceptives was significantly associated with HPV HR
infection. These results are consistent with a meta-
analysis by the International Agency on Research of
Cancer [32].
Sample testing
In our study, primary screening was performed with
HC2 because of high clinical sensitivity and specificity
[33]. The occurrence of discordant results in our assay
algorithm (i.e., HC2 positive with no HR HPV identified)
may be attributable to false positive results with HC2 as
exemplified by the 2 LR HPV mono-infections [34-36].
This would explain negative results in the subsequent
Genotyping Kit HPV GP. Another possible explanation
for a discordant result could be a sequence variation in
the L1 target area, disrupting the GP5+/6 + − PCR target
[37]. Because of the very high analytical sensitivity, we
used the SPF10-LiPA25, version 1, for discrepancy ana-
lysis between the Genotyping Kit HPV GP and HC2
[13,34], resulting in additional 17/27 (63.0%) genotyped
samples. This may be related to the superior analytical
sensitivity of the SPF10-LiPA25, version 1, compared to
GP5+/6 + −primer based assays [13].
Limitations and strengths
Our study has certain limitations. First, patients were re-
cruited in the single setting of Attat hospital and mor-
bidity may be higher than in the general population.
However, representative Ethiopian data are currently
lacking, making our report the most comprehensive on
HPV prevalence in Ethiopia yet. Second, no cytological
evaluation was performed that would allow further sam-
ple stratification. However, this study focussed on HPV
DNA testing in order to assess the burden of HPV in-
fection and build baseline data prior to the imple-
mentation of HPV vaccination programmes to allowmonitoring eventual changes in HPV prevalence and
genotype distribution.
Third, the restriction of HPV genotyping to HC2 HR
positive samples might have led to a bias in HPV type
distribution and presentation.Perspectives
Health economic models for evaluating the potential
benefit of implementing HPV vaccination programs indi-
cate that such interventions may be very cost-effective in
Eastern Africa [4]. Challenges in the implementation must
be considered, such as vaccine delivery (e.g. through
health centers and schools), vaccine effect monitoring
(e.g. sampling method, laboratory infrastructure, means of
registration) and a vast cultural and regional diversity
within Ethiopia. Corresponding analyses for Ethiopia
are currently lacking and should thus be conducted
before HPV vaccine delivery can finally be advocated. If
Ethiopian large-scale introduction of HPV vaccination is
envisaged, our data on the HPV genotype distribution
would enable monitoring associated benefits and harms in
rural settings.Conclusion
Our results show a high frequency of at least 10% HPV
HR infection across all age groups, which is an impor-
tant risk factor for cervical cancer development. The
predominant HPV genotype that is already targeted in
current HPV vaccination was 16 (24.4%). For future use
of HPV vaccines, our study provides the first share of
important baseline data that would enable monitoring of
interim HPV vaccination effects, such as changes in
HPV prevalence and genotype distribution.Ethical approval
The ethics committee of the Medical Association
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